APA (7th ed.) Citation

Narula, N., & Reinisch, W. (2016). Letter: Comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply. Alimentary Pharmacology & Therapeutics, 44(7), 772. https://doi.org/10.1111/apt.13768

Chicago Style (17th ed.) Citation

Narula, N., and W. Reinisch. "Letter: Comparative Safety and Efficacy of Infliximab Vs. Adalimumab in Crohn's Disease - Should One Consider Disease Location? Authors' Reply." Alimentary Pharmacology & Therapeutics 44, no. 7 (2016): 772. https://doi.org/10.1111/apt.13768.

MLA (9th ed.) Citation

Narula, N., and W. Reinisch. "Letter: Comparative Safety and Efficacy of Infliximab Vs. Adalimumab in Crohn's Disease - Should One Consider Disease Location? Authors' Reply." Alimentary Pharmacology & Therapeutics, vol. 44, no. 7, 2016, p. 772, https://doi.org/10.1111/apt.13768.